Legal group urges CMS to cover BiDil for black Medicare patients

Group contends CMS is promoting a less expensive generic substitute.

The Centers for Medicare and Medicaid Services' decision not to provide insurance coverage for Bidil (isosorbide dinitrate/hydralazine, Nitromed) when it is the only drug approved to treat African Americans with heart failure is racially insensitive. So contends the Washington Legal Foundation (WLF), a public interest law and policy center. So WLF has petitioned CMS to revise its reimbursement policies for the cardiovascular drug. WLF said CMS is promoting a less expensive generic substitute, even though the Food and Drug Administration has determined that there is no interchangeable product for BiDil.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, clickhere.